Cargando…
Apalutamide for patients with metastatic castration-sensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial
Ethnicity might be associated with treatment outcomes in advanced prostate cancer. This study aimed to evaluate the efficacy and safety of androgen deprivation therapy (ADT) combined with apalutamide in East Asians with metastatic castration-sensitive prostate cancer (mCSPC). The original phase 3 Ta...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887099/ https://www.ncbi.nlm.nih.gov/pubmed/34259202 http://dx.doi.org/10.4103/aja.aja_64_21 |
_version_ | 1784660821355266048 |
---|---|
author | Chung, Byung Ha Huang, Jian Ye, Zhang-Qun He, Da-Lin Uemura, Hirotsugu Arai, Gaku Kim, Choung Soo Zhang, Yuan-Yuan Koroki, Yusoke Jeong, SuYeon Mundle, Suneel Triantos, Spyros McCarthy, Sharon Chi, Kim N Ye, Ding-Wei |
author_facet | Chung, Byung Ha Huang, Jian Ye, Zhang-Qun He, Da-Lin Uemura, Hirotsugu Arai, Gaku Kim, Choung Soo Zhang, Yuan-Yuan Koroki, Yusoke Jeong, SuYeon Mundle, Suneel Triantos, Spyros McCarthy, Sharon Chi, Kim N Ye, Ding-Wei |
author_sort | Chung, Byung Ha |
collection | PubMed |
description | Ethnicity might be associated with treatment outcomes in advanced prostate cancer. This study aimed to evaluate the efficacy and safety of androgen deprivation therapy (ADT) combined with apalutamide in East Asians with metastatic castration-sensitive prostate cancer (mCSPC). The original phase 3 Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) trial was conducted at 260 sites in 23 countries. This subgroup analysis included patients enrolled in 62 participating centers in China, Japan, and Korea. Radiographic progression-free survival (PFS), time to prostate-specific antigen (PSA) progression, and PSA changes from baseline were compared between groups in the East Asian population. The intent-to-treat East Asian population included 111 and 110 participants in the apalutamide and placebo groups, respectively. The 24-month radiographic PFS rates were 76.1% and 52.3% in the apalutamide and placebo groups, respectively (apalutamide vs placebo: hazard ratio [HR] = 0.506; 95% confidence interval [CI], 0.302–0.849; P = 0.009). Median time to PSA progression was more favorable with apalutamide than placebo (HR = 0.210; 95% CI, 0.124–0.357; P < 0.001). Median maximum percentages of PSA decline from baseline were 99.0% and 73.9% in the apalutamide and placebo groups, respectively. The most common adverse event (AE) was rash in the apalutamide group, with a higher rate than that in the placebo group (37.3% vs 9.1%). The most common grade 3 or 4 AEs were rash (12 [10.9%]) and hypertension (12 [10.9%]) for apalutamide. The efficacy and safety of apalutamide in the East Asian subgroup of the TITAN trial are consistent with the global results. |
format | Online Article Text |
id | pubmed-8887099 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-88870992022-03-10 Apalutamide for patients with metastatic castration-sensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial Chung, Byung Ha Huang, Jian Ye, Zhang-Qun He, Da-Lin Uemura, Hirotsugu Arai, Gaku Kim, Choung Soo Zhang, Yuan-Yuan Koroki, Yusoke Jeong, SuYeon Mundle, Suneel Triantos, Spyros McCarthy, Sharon Chi, Kim N Ye, Ding-Wei Asian J Androl Original Article Ethnicity might be associated with treatment outcomes in advanced prostate cancer. This study aimed to evaluate the efficacy and safety of androgen deprivation therapy (ADT) combined with apalutamide in East Asians with metastatic castration-sensitive prostate cancer (mCSPC). The original phase 3 Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) trial was conducted at 260 sites in 23 countries. This subgroup analysis included patients enrolled in 62 participating centers in China, Japan, and Korea. Radiographic progression-free survival (PFS), time to prostate-specific antigen (PSA) progression, and PSA changes from baseline were compared between groups in the East Asian population. The intent-to-treat East Asian population included 111 and 110 participants in the apalutamide and placebo groups, respectively. The 24-month radiographic PFS rates were 76.1% and 52.3% in the apalutamide and placebo groups, respectively (apalutamide vs placebo: hazard ratio [HR] = 0.506; 95% confidence interval [CI], 0.302–0.849; P = 0.009). Median time to PSA progression was more favorable with apalutamide than placebo (HR = 0.210; 95% CI, 0.124–0.357; P < 0.001). Median maximum percentages of PSA decline from baseline were 99.0% and 73.9% in the apalutamide and placebo groups, respectively. The most common adverse event (AE) was rash in the apalutamide group, with a higher rate than that in the placebo group (37.3% vs 9.1%). The most common grade 3 or 4 AEs were rash (12 [10.9%]) and hypertension (12 [10.9%]) for apalutamide. The efficacy and safety of apalutamide in the East Asian subgroup of the TITAN trial are consistent with the global results. Wolters Kluwer - Medknow 2021-07-13 /pmc/articles/PMC8887099/ /pubmed/34259202 http://dx.doi.org/10.4103/aja.aja_64_21 Text en Copyright: ©The Author(s)(2021) https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Chung, Byung Ha Huang, Jian Ye, Zhang-Qun He, Da-Lin Uemura, Hirotsugu Arai, Gaku Kim, Choung Soo Zhang, Yuan-Yuan Koroki, Yusoke Jeong, SuYeon Mundle, Suneel Triantos, Spyros McCarthy, Sharon Chi, Kim N Ye, Ding-Wei Apalutamide for patients with metastatic castration-sensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial |
title | Apalutamide for patients with metastatic castration-sensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial |
title_full | Apalutamide for patients with metastatic castration-sensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial |
title_fullStr | Apalutamide for patients with metastatic castration-sensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial |
title_full_unstemmed | Apalutamide for patients with metastatic castration-sensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial |
title_short | Apalutamide for patients with metastatic castration-sensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial |
title_sort | apalutamide for patients with metastatic castration-sensitive prostate cancer in east asia: a subgroup analysis of the titan trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887099/ https://www.ncbi.nlm.nih.gov/pubmed/34259202 http://dx.doi.org/10.4103/aja.aja_64_21 |
work_keys_str_mv | AT chungbyungha apalutamideforpatientswithmetastaticcastrationsensitiveprostatecancerineastasiaasubgroupanalysisofthetitantrial AT huangjian apalutamideforpatientswithmetastaticcastrationsensitiveprostatecancerineastasiaasubgroupanalysisofthetitantrial AT yezhangqun apalutamideforpatientswithmetastaticcastrationsensitiveprostatecancerineastasiaasubgroupanalysisofthetitantrial AT hedalin apalutamideforpatientswithmetastaticcastrationsensitiveprostatecancerineastasiaasubgroupanalysisofthetitantrial AT uemurahirotsugu apalutamideforpatientswithmetastaticcastrationsensitiveprostatecancerineastasiaasubgroupanalysisofthetitantrial AT araigaku apalutamideforpatientswithmetastaticcastrationsensitiveprostatecancerineastasiaasubgroupanalysisofthetitantrial AT kimchoungsoo apalutamideforpatientswithmetastaticcastrationsensitiveprostatecancerineastasiaasubgroupanalysisofthetitantrial AT zhangyuanyuan apalutamideforpatientswithmetastaticcastrationsensitiveprostatecancerineastasiaasubgroupanalysisofthetitantrial AT korokiyusoke apalutamideforpatientswithmetastaticcastrationsensitiveprostatecancerineastasiaasubgroupanalysisofthetitantrial AT jeongsuyeon apalutamideforpatientswithmetastaticcastrationsensitiveprostatecancerineastasiaasubgroupanalysisofthetitantrial AT mundlesuneel apalutamideforpatientswithmetastaticcastrationsensitiveprostatecancerineastasiaasubgroupanalysisofthetitantrial AT triantosspyros apalutamideforpatientswithmetastaticcastrationsensitiveprostatecancerineastasiaasubgroupanalysisofthetitantrial AT mccarthysharon apalutamideforpatientswithmetastaticcastrationsensitiveprostatecancerineastasiaasubgroupanalysisofthetitantrial AT chikimn apalutamideforpatientswithmetastaticcastrationsensitiveprostatecancerineastasiaasubgroupanalysisofthetitantrial AT yedingwei apalutamideforpatientswithmetastaticcastrationsensitiveprostatecancerineastasiaasubgroupanalysisofthetitantrial |